Valentina Gerber

Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.

T. Todenhöfer, A. Stenzl, J. Hennenlotter, 2012, Anticancer research.

Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer

T. Todenhöfer, A. Stenzl, J. Bedke, 2018, Diagnostic cytopathology.

XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence

A. Stenzl, A. Merseburger, J. Hennenlotter, 2012, World Journal of Urology.

Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer

M. Heni, H. Häring, T. Todenhöfer, 2012, PloS one.

Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.

T. Todenhöfer, A. Stenzl, J. Hennenlotter, 2014, Urologic oncology.

Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

Christian Schwentner, Arnulf Stenzl, Jörg Hennenlotter, 2013, World Journal of Urology.

1320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE MEVALONATE PATHWAY FOR DISEASE PROGRESSION

T. Todenhöfer, A. Stenzl, J. Hennenlotter, 2012 .

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer

G. Russo, S. Cimino, T. Todenhöfer, 2019, Disease markers.